Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,153 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,153 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $35.30, for a total value of $146,600.90. Following the transaction, the insider now directly owns 161,497 shares in the company, valued at approximately $5,700,844.10. This represents a 2.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $3.01 during trading hours on Tuesday, hitting $41.94. The company had a trading volume of 16,419,084 shares, compared to its average volume of 11,104,599. The firm has a 50 day simple moving average of $29.35 and a 200 day simple moving average of $22.70. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $41.98. The firm has a market capitalization of $9.16 billion, a price-to-earnings ratio of 95.32 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HIMS. Piper Sandler increased their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $25.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Main Management ETF Advisors LLC purchased a new position in Hims & Hers Health in the 3rd quarter worth $672,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Hims & Hers Health in the 3rd quarter worth about $604,000. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health during the third quarter valued at $5,531,000. Royce & Associates LP raised its holdings in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Finally, Versor Investments LP bought a new stake in shares of Hims & Hers Health in the third quarter worth approximately $634,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.